First review of the potential renoprotective effects and mechanisms of GLP-1R agonists and DPP-4 inhibitors in preclinical studies and in early clinical studies involving patients with diabetes
MetS patients had higher FMD
The aim of this narrative review is to explore the therapeutic potential of GLP-1RAs in the management of OSA, by summarizing available preclinical and clinical evidence on their efficacy, mechanisms, and potential impact on OSA comorbidities
* Correspondence: Remigiusz Domin, [email protected] These authors have contributed equally to this work and share senior authorship Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers
However, its role is more about optimizing the function of existing cells and promoting healthy tissue remodeling, rather than direct "stem cell activation" in the broad sense